In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to share industry updates and Mayo Clinic’s test development success in 2025. Later, Dr. Pritt welcomes Janelle Santos, M.D., a maternal-fetal medicine specialist at Mayo Clinic, to discuss how she uses a preeclampsia test to care for her patients.

• Public policy insights for 2026 (00:34): Dr. Bill Morice shares insights on reimbursement and AI-related policy developments following an association meeting in Washington, D.C. 
• An unprecedented year for test development (04:45): Discover how Mayo Clinic’s record year for test development delivers value to Mayo Clinic’s patients and Mayo Clinic Laboratories’ clients.
• Novel preeclampsia testing (08:13): Learn how new clinical testing helps physicians improve outcomes for women at risk for preeclampsia and their babies.

Note: Information in this post was accurate at the time of its posting.

Resources

• 4 steps to establishing a new approach to innovation 
• Innovation beyond the bench: Translating science into better diagnostics and outcomes
• Preeclampsia: Empowering confident decision-making through preeclampsia risk assessment
• Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. 
• Preeclampsia sFlt-1/PIGF Ratio, Serum (Mayo ID: PERA)